(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 1.92% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Charles River Laboratories International's revenue in 2026 is $3,998,987,000.On average, 18 Wall Street analysts forecast CRL's revenue for 2026 to be $188,568,544,400, with the lowest CRL revenue forecast at $182,410,229,912, and the highest CRL revenue forecast at $198,402,752,032. On average, 18 Wall Street analysts forecast CRL's revenue for 2027 to be $192,960,520,624, with the lowest CRL revenue forecast at $184,033,351,560, and the highest CRL revenue forecast at $205,229,410,728.
In 2028, CRL is forecast to generate $203,367,594,720 in revenue, with the lowest revenue forecast at $191,719,309,952 and the highest revenue forecast at $216,018,395,800.